Shares of TG Therapeutics Inc. (NASDAQ:TGTX) were up 4.7% during mid-day trading on Thursday . The stock traded as high as $5.74 and last traded at $5.75, with a volume of 254,438 shares trading hands. The stock had previously closed at $5.49.

Several analysts have issued reports on TGTX shares. Brean Capital restated a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, June 7th. FBR & Co reiterated a “buy” rating on shares of TG Therapeutics in a research report on Thursday, April 14th. SunTrust Banks Inc. assumed coverage on TG Therapeutics in a research report on Friday, May 27th. They set a “buy” rating and a $18.00 price target on the stock. Zacks Investment Research cut TG Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 14th. Finally, Roth Capital reiterated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research report on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $22.75.

The firm’s market capitalization is $309.86 million. The stock has a 50-day moving average price of $5.98 and a 200 day moving average price of $7.82.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by $0.04. On average, equities research analysts anticipate that TG Therapeutics Inc. will post ($1.23) earnings per share for the current fiscal year.

An institutional investor recently raised its position in TG Therapeutics stock. New York State Common Retirement Fund raised its stake in shares of TG Therapeutics Inc. (NASDAQ:TGTX) by 23.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 223,851 shares of the biopharmaceutical company’s stock after buying an additional 42,933 shares during the period. New York State Common Retirement Fund owned 0.43% of TG Therapeutics worth $2,671,000 as of its most recent SEC filing.

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.